ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PBM / insiders
MCRB (40) ACTU (35) KYNB (32) NEUP (31) ⌘ Pro Terminal →

Psyence Biomedical Ltd. (PBM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.18 -3.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.15

Psyence Biomedical Ltd. (PBM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $17.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Psyence Biomedical Ltd. (NASDAQ: PBM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $3.18 (-3.93% 1D, market cap $17.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PBM ranks #343 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBM compare to MCRB and ACTU in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MCRB (Seres Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $17.8M) and ACTU (Actuate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M). Among the 5-stock peer group, PBM leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBM?
▼

For Psyence Biomedical Ltd. (PBM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.15 (-0.90%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.3% Base Target
$129 Bull$3 Base$2 Bear
📬 FREE PBM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY PBM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($492.7K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$4.55-6.8% Next Q
Q2 (-2Q)
51
Grade C-$4.24-29% Next Q
Q3 (-1Q)
49
Grade D$3.01+5.6% Next Q
Current
46
Grade D$3.18-6.1% Hist 90D α
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PBM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PBM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.79) and Max Pain ($3.34) forces dealer call-delta covering toward $128.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PBM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PBM Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PBM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PBM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PBM)

  • ✓Walkthrough of PBM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PBM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.47%▲ ASCENDING TRIANGLE
2026-11-03O $3.61H $3.61L $3.18C $3.18VOL 46.6K
SUP: $2.70SMA50: $4.79SMA200: $3.98
$80.63$59.49$38.35$17.20$-3.94SUP $2.70$3.182026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBM Butterfly Map → + Track PBM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PBM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PBM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBM)

Health Care Rank #343 of 1015 ⚔️ MCRB vs PBM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBM vs. MCRB, ACTU, KYNB, NEUP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Psyence Biomedical Ltd. (PBM) ranks #343 by composite RQD confidence (46/100, grade D) and #837 by equity capitalization ($17.6M). Within this direct 5-issuer industry benchmark cohort, PBM leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. PBM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PBM ACTIVE
Psyence Biomedical Ltd.
D 46/100 — — — -3.93% $17.6M Benchmark Subject
MCRB
Seres Therapeutics Inc.
D- 40/100 — — -35.0% +3.39% $17.8M /mcrb-vs-pbm →
ACTU
Actuate Therapeutics Inc.
D- 35/100 — — -35.0% +2.06% $18.4M /actu-vs-pbm →
KYNB
Kyntra Bio Inc.
E 32/100 — 91.4% -35.0% -2.41% $18.5M /kynb-vs-pbm →
NEUP
Neuphoria Therapeutics Inc.
E 31/100 — — -11.8% -0.33% $16.5M /neup-vs-pbm →

2. PBM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Psyence Biomedical Ltd. (PBM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $17.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PBM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Psyence Biomedical Ltd. (NASDAQ: PBM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $3.18 (-3.93% 1D, market cap $17.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, PBM ranks #343 in composite RQD confidence.

How does PBM compare to MCRB and ACTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MCRB (Seres Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $17.8M) and ACTU (Actuate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M). Among the 5-stock peer group, PBM leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBM?

For Psyence Biomedical Ltd. (PBM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #343 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBM trading relative to its 50-day, 200-day, and 52-week technical levels?

PBM last traded at $3.18 (-3.93% on volume of 116,091 shares), positioning the stock -33.61% below its 50-day simple moving average ($4.79) and -20.10% below its 200-day simple moving average ($3.98). Across its 52-week range of $1.92 to $122.85, PBM sits at the 1.0% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.78 to $3.58).

Direct Sub-Reports: PBM RQD Cockpit PBM 12M Forecast PBM Earnings & Move PBM Dividends & DRIP PBM Insiders & 13F PBM Whale Options PBM Profit Sankey PBM News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

PBM — Psyence Biomedical Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Psyence Biomedical Ltd. (PBM) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $3.18 (-3.93% 1D, market capitalization $17.6M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Psyence Biomedical Ltd. (PBM) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. Per the recent news wire, the company has invested in PsyLabs and entered a partnership with DEA-registered Benuvia, and a headline references an ibogaine manufacturing deal. — for product detail, customer base, or revenue model beyond these references.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.92 – $122.85 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. The only sector context available is Health Care / Biotechnology: Pharmaceutical Preparations. Investors should note that the news-linked PsyLabs and Benuvia relationships are the only ecosystem references in the source, and their operational dependencies are not documented.

  • Key Question #1: Can PBM sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $122.85 52-week high?
  • Key Question #3: How sensitive is PBM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PBM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Psyence Biomedical Ltd. (PBM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PBM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PBM Bull vs. Bear Conversation Board — What's Your Call at $3.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PBM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PBM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $4.24 (+28.1%)
📌 Pinned Debate

The forensic balance sheet scores 13/20 with Altman Z 2.5 and Debt/Equity 0.5, the strongest pillar in the rating.

Picked up a starter position in PBM in my $100K Virtual Cash book at $3.31. The forensic balance sheet scores 13/20 with Altman Z 2.5 and Debt/Equity 0.5, the strongest pillar in the rating.. Trading inside a $1.92–$122.85 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@TapeReader_Pro Agree on the RQD 46/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.31 and keeping dry powder in case we test $3.08.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.65 (-19.9%)
Spot @ $3.31

Whale 13F flow scores only 3/20 and ROIC and FCF yield are both 0%, leaving little institutional or cash-generation support.

Whale 13F flow scores only 3/20 and ROIC and FCF yield are both 0%, leaving little institutional or cash-generation support.. Look at the math on PBM: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $2.91 before getting long.

LIVE TAPE